Clinical Trial Update: Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy of daily-dose consensus interferon plus ribavirin for chronic hepatitis C has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Consensus interferon
• Ribavirin (ribavirin)

Snippet

Sponsor: Bausch Health Americas, Inc. | Conditions: Chronic Hepatitis C | Phase 3 | Status: COMPLETED